Obsessive-compulsive disorder in schizophrenia - Clinical characteristics and treatment

被引:114
|
作者
Poyurovsky, M
Weizman, A
Weizman, R
机构
[1] Tirat Carmel Mental Hlth Ctr, IL-30200 Tirat Carmel, Israel
[2] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
[3] Felsenstein Med Res Ctr, Lab Biol Psychiat, Petah Tiqwa, Israel
[4] Geha Mental Hlth Ctr, Petah Tiqwa, Israel
[5] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[6] Tel Aviv Mental Hlth Ctr, Tel Aviv, Israel
关键词
D O I
10.2165/00023210-200418140-00004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is a considerable overlap of schizophrenia and obsessive-compulsive disorder (OCD) in the structural and functional brain abnormalities involved, role of the dopamine/serotonin neurotransmitter systems, and some demographic and clinical characteristics. Although OCD co-occurs in a substantial proportion of schizophrenia patients, a systematic evaluation of the clinical features and treatment of this population is lacking. This review critically evaluates findings of recent studies pertaining to the rate of occurrence of OCD or obsessive-compulsive symptoms (OCS) in schizophrenia and the clinical characterisation of the schizo-obsessive subtype. Specifically, interrelationships between obsessive-compulsive and schizophrenic symptoms in terms of temporal relationships and their association with specific schizophrenia subtypes and the effect of OCS on the severity of schizophrenia symptoms are addressed. In the absence of evidence-based data, tentative therapeutic approaches in this difficult-to-treat patient subgroup are suggested. These include monotherapy with atypical antipsychotic agents or a combination of either typical or atypical antipsychotics with SSRIs or clomipramine. The clinical characteristics of antipsychotic-induced OCS/OCD are also presented to facilitate identification and management of this rare but clinically significant adverse effect. Finally, future directions of research in schizophrenia-OCD comorbidity relevant to clinical practice are discussed.
引用
收藏
页码:989 / 1010
页数:22
相关论文
共 50 条
  • [1] Clinical characteristics in obsessive-compulsive disorder with schizophrenia
    Özdemir, Ö
    Tükel, R
    Türksoy, N
    Üçok, A
    [J]. COMPREHENSIVE PSYCHIATRY, 2003, 44 (04) : 311 - 316
  • [2] Clinical philosophy in the treatment of paranoid schizophrenia and obsessive-compulsive disorder
    Gole, Markus
    [J]. ARCHIVES OF PSYCHIATRY AND PSYCHOTHERAPY, 2015, 17 (04): : 53 - 60
  • [3] Schizophrenia and Obsessive-Compulsive Disorder
    Devulapalli, Kavi
    Nasrallah, Henry A.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (11): : 1407 - 1408
  • [4] Obsessive-compulsive disorder in schizophrenia
    Tibbo, P
    Kroetsch, M
    Chue, P
    Warneke, L
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2000, 34 (02) : 139 - 146
  • [5] Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder
    Ackerman, DL
    Greenland, S
    Bystritsky, A
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) : 185 - 192
  • [6] Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia
    Devi, Sugnyani
    Rao, Naren P.
    Badamath, Suresh
    Chandrashekhar, C. R.
    Reddy, Y. C. Janardhan
    [J]. COMPREHENSIVE PSYCHIATRY, 2015, 56 : 141 - 148
  • [7] Clinical characteristics of obsessive compulsive disorder with schizophrenia
    Koo, M. S.
    Cheon, K. A.
    Jun, J. Y.
    Kim, C. H.
    [J]. EUROPEAN PSYCHIATRY, 2007, 22 : S218 - S218
  • [8] Clinical characteristics of obsessive compulsive disorder with schizophrenia
    Koo, M. -S.
    Kim, C-H.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 91 - 91
  • [9] Clinical characteristics of obsessive compulsive disorder with schizophrenia
    Koo, M. -S.
    Kim, C. H.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 50 - 50
  • [10] Clinical characteristics of obsessive compulsive disorder with schizophrenia
    Koo, M. -S.
    Suh, H. S.
    Kim, C. H.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 282 - 282